We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 13 SEPTEMBER 2011
Federal Circuit Creates "Palpable" Confusion Surrounding Patent Eligibility

Morrison Foerster
Contributor

Morrison Foerster
With approximately 1,000 lawyers in 19 offices, Morrison & Foerster is a preeminent global law firm...
View firm profileIn yet another decision examining the boundaries of patent-eligible subject matter under 35 U.S.C. § 101, the Federal Circuit determined in Classen Immunotherapies v. Biogen IDEC that two representative claims directed to comparing immunization schedules, choosing a schedule, and immunizing a patient based on that schedule, constitute patent-eligible subject matter.
United StatesIntellectual Property







